ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 317 filers reported holding ROYALTY PHARMA PLC in Q3 2022. The put-call ratio across all filers is 0.29 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,820,106 | -42.6% | 214,448 | -35.0% | 0.04% | -35.8% |
| Q2 2023 | $10,146,293 | +1167.7% | 330,068 | +1385.9% | 0.07% | +1240.0% |
| Q1 2023 | $800,356 | -92.0% | 22,214 | -91.3% | 0.01% | -91.5% |
| Q4 2022 | $10,062,108 | +104.6% | 254,608 | +108.0% | 0.06% | +110.7% |
| Q3 2022 | $4,919,000 | +375.7% | 122,432 | +398.0% | 0.03% | +366.7% |
| Q2 2022 | $1,034,000 | -75.3% | 24,586 | -77.1% | 0.01% | -82.9% |
| Q1 2022 | $4,184,000 | +173.1% | 107,404 | +179.5% | 0.04% | +133.3% |
| Q4 2021 | $1,532,000 | -52.2% | 38,434 | -56.6% | 0.02% | -62.5% |
| Q3 2021 | $3,203,000 | -63.2% | 88,640 | -58.3% | 0.04% | -59.2% |
| Q2 2021 | $8,710,000 | +418.5% | 212,488 | +451.8% | 0.10% | +345.5% |
| Q1 2021 | $1,680,000 | +211.7% | 38,505 | +257.3% | 0.02% | +214.3% |
| Q4 2020 | $539,000 | -81.1% | 10,776 | -84.1% | 0.01% | -83.3% |
| Q3 2020 | $2,847,000 | +2040.6% | 67,665 | +2364.1% | 0.04% | +2000.0% |
| Q2 2020 | $133,000 | – | 2,746 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $244,378,000 | 79.54% |
| Vantage Consulting Group Inc | 7,862,542 | $284,152,000 | 60.85% |
| Memorial Sloan Kettering Cancer Center | 2,680,644 | $96,878,000 | 60.36% |
| Indie Asset Partners, LLC | 701,323 | $25,346,000 | 20.53% |
| HARVARD MANAGEMENT CO INC | 7,142,856 | $258,143,000 | 15.13% |
| Bleichroeder LP | 1,115,980 | $40,332,000 | 6.55% |
| Overbrook Management Corp | 785,132 | $28,375,000 | 6.16% |
| Geo Capital Gestora de Recursos Ltd | 194,305 | $7,022,000 | 3.21% |
| Brown University | 621,759 | $22,470,000 | 3.05% |
| Graypoint LLC | 610,584 | $22,067,000 | 2.71% |